163 related articles for article (PubMed ID: 35293306)
1. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
Charlton V
Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
[TBL] [Abstract][Full Text] [Related]
2. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
3. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
4. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
5. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
6. Exorcising the positivist ghost in the priority-setting machine: NICE and the demise of the 'social value judgement'.
Charlton V; Weale A
Health Econ Policy Law; 2021 Oct; 16(4):505-511. PubMed ID: 33568251
[TBL] [Abstract][Full Text] [Related]
7. Modifying NICE's Approach to Equity Weighting.
Paulden M; McCabe C
Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
[TBL] [Abstract][Full Text] [Related]
8. Some inconsistencies in NICE's consideration of social values.
Paulden M; O'Mahony JF; Culyer AJ; McCabe C
Pharmacoeconomics; 2014 Nov; 32(11):1043-53. PubMed ID: 25145802
[TBL] [Abstract][Full Text] [Related]
9. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
10. An empirical ethics study of the coherence of NICE technology appraisal policy and its implications for moral justification.
Charlton V; DiStefano M
BMC Med Ethics; 2024 Mar; 25(1):28. PubMed ID: 38448909
[TBL] [Abstract][Full Text] [Related]
11. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
Davies E; Littlejohns P
J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
[TBL] [Abstract][Full Text] [Related]
12. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
13. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
[TBL] [Abstract][Full Text] [Related]
14. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
15. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
16. The NICE cost-effectiveness threshold: what it is and what that means.
McCabe C; Claxton K; Culyer AJ
Pharmacoeconomics; 2008; 26(9):733-44. PubMed ID: 18767894
[TBL] [Abstract][Full Text] [Related]
17. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
18. The ethics of grandfather clauses in healthcare resource allocation.
Wester G; Gibson Rand LZ; Lu C; Sheehan M
Bioethics; 2021 Feb; 35(2):151-160. PubMed ID: 33043477
[TBL] [Abstract][Full Text] [Related]
19. Innovation as a value in healthcare priority-setting: the UK experience.
Charlton V; Rid A
Soc Justice Res; 2019; 32(2):208-238. PubMed ID: 31281204
[TBL] [Abstract][Full Text] [Related]
20. Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis.
Hale G; Morris J; Barker-Yip J
J Comp Eff Res; 2023 Nov; 12(11):e230093. PubMed ID: 37724717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
